zenocutuzumab

Zenocutuzumab is a humanized bispecific monoclonal antibody that targets both HER2 (human epidermal growth factor receptor 2) and HER3 (human epidermal growth factor receptor 3). It is specifically designed to treat advanced or metastatic solid tumors—most notably non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma—that harbor neuregulin 1 (NRG1) gene fusions. Zenocutuzumab works by binding simultaneously to HER2 and HER3 on the surface of tumor cells, blocking their interaction and preventing NRG1-driven oncogenic signaling through the PI3K/AKT/mTOR pathway. This dual blockade inhibits tumor cell proliferation and survival. Additionally, zenocutuzumab enhances immune-mediated killing of cancer cells via antibody-dependent cellular cytotoxicity (ADCC). The drug is administered intravenously every two weeks. It was granted accelerated FDA approval in December 2024 as the first targeted therapy for NRG1 fusion-positive NSCLC and pancreatic cancer[4][5][6][8][9].

Brand names

Bizengrizenocutuzumab-zbco

Other names

zenocutuzumab-zbco